Baseline Airflow Obstruction in COPD
Chronic inflammation narrows airways and traps air on exhale.
- ~45%: Typical FEV1 % predicted (moderate-severe range)
- <0.70: FEV1/FVC ratio (defines airflow obstruction)
- Hypertrophied: Airway smooth muscle (chronic bronchoconstriction)
- Elevated: Air trapping (residual volume rises)
Why the lumen narrows
Inflammation thickens airway walls and thickens mucus.
Spirometry signature
Reduced FEV1/FVC ratio confirms obstructive, not restrictive, disease.
A ratio under 0.70 post-bronchodilator is the GOLD diagnostic threshold.
LAMA — Long-Acting Muscarinic Antagonist
Tiotropium blocks acetylcholine at M3 receptors on smooth muscle.
- M3: Target receptor (muscarinic subtype)
- 24 h: Duration of action (once-daily dosing)
- Trough-favoring: Effect type (sustained bronchodilation)
- cGMP ↓: Mechanism (blocks contraction signal)
Blocking the contraction signal
Acetylcholine normally binds M3 receptors, triggering muscle contraction.
Sustained trough effect
Slow receptor dissociation keeps airways open between doses.
Tiotropium's M3 dissociation half-life exceeds 34 hours.
LABA — Long-Acting Beta-2 Agonist
Salmeterol stimulates beta-2 receptors, raising cAMP to relax muscle.
- β2: Target receptor (adrenergic subtype)
- cAMP ↑: Second messenger (triggers relaxation)
- Gradual: Onset profile (sustained over 12h+)
- Peak-favoring: Effect type (boosts flow rates)
cAMP-driven relaxation
Beta-2 stimulation activates adenylyl cyclase, relaxing smooth muscle.
Complementary kinetics
LABA favors peak flow while LAMA favors sustained trough.
Distinct receptor pathways make LABA and LAMA mechanistically additive.
Combined LABA/LAMA Bronchodilation
Two receptor pathways together widen airways more than either alone.
- +50-100 mL: FEV1 gain vs monotherapy (typical add-on benefit)
- Reduced: Hyperinflation (lower residual volume)
- Lower: Exacerbation rate (vs single bronchodilator)
- Once daily: Dosing (fixed-dose inhaler)
Additive receptor blockade and stimulation
Blocking contraction and stimulating relaxation compound the widening effect.
Clinical payoff
Dual therapy improves trapped air and daily symptom burden.
Trials show LABA/LAMA combinations outperform either drug class alone.
GOLD Spirometric Staging
Post-bronchodilator FEV1 % predicted sorts COPD into four severity grades.
- ≥80%: GOLD 1 (mild)
- 50-79%: GOLD 2 (moderate)
- 30-49%: GOLD 3 (severe)
- <30%: GOLD 4 (very severe)
Staging requires obstruction first
FEV1/FVC must be under 0.70 before staging by FEV1 applies.
Why staging matters
Stage guides bronchodilator intensity and add-on therapy choices.
Bronchodilators can shift measured FEV1 enough to change GOLD stage.